Shares of Immunovant Inc. (IMVT), a clinical-stage immunology company developing medicines for people with autoimmune diseases, have lost more than 50% of their value from their 52-week high of $39.55, recorded last February, and trade around $19.
The company has a couple of clinical trial catalysts related to its lead drug candidate, Batoclimab, to watch this quarter.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com